Marjolein V. D. P.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Phase 3 Randomized Study of Nivolumab and Ipilimumab with Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
- Comparison of Sotorasib Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in PD-L1 Negative KRAS p.G12C Positive Advanced Non-Squamous NSCLC
- Phase 3 Randomized Open‑Label Study of KITE‑753 Versus Axicabtagene Ciloleucel in Relapsed or Refractory Large B‑Cell Lymphoma After First‑Line Therapy
Data & Insights
Has run more than one trial at 312 of 580 partner sites.
Specializations
Non-Small Cell Lung Cancer
The investigator specializes in researching advanced treatments for non-small cell lung cancer (NSCLC), with particular focus on various molecular subtypes including EGFR mutations, ALK-positive, and KRAS G12C mutations.
- Advanced and Metastatic NSCLC
- Oligometastatic Disease
- Brain Metastases Management
Their research encompasses innovative therapeutic approaches including targeted therapies, immunotherapy combinations, and maintenance treatments.
Small Cell Lung Cancer
The investigator conducts research in extensive-stage small cell lung cancer (ES-SCLC), exploring novel treatment combinations and therapeutic strategies.
- First-line Therapy
- Combination Approaches
- Relapsed SCLC Treatment
Their work includes evaluation of innovative therapeutic agents and immunotherapy combinations for this aggressive form of lung cancer.
Precision Medicine
The investigator focuses on developing personalized treatment approaches based on specific molecular markers and genetic alterations in lung cancer.
- Biomarker-Driven Therapy
- Targeted Treatment Resistance
- Novel Drug Development
Their research includes investigation of treatment strategies for specific genetic mutations and exploration of resistance mechanisms.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.